학술논문
The 12‐week kinetics of anti‐SARS‐CoV‐2 antibodies in different haematological cancers after vaccination with BNT162b2.
Document Type
Article
Author
Source
Subject
*CANCER vaccines
*MYELOFIBROSIS
*COVID-19 vaccines
*SARS-CoV-2
*IMMUNOGLOBULINS
*COVID-19
*
*
*
*
*
Language
ISSN
0007-1048
Abstract
I TableGeometric mean concentrations of anti-SARS-CoV-2 IgG and response rates according to seven different cohorts of haematological malignancy patients compared to a control cohort at 5 and 12 weeks after BNT162b2 vaccination. Keywords: severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); BNT162b2; haematological cancers EN severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) BNT162b2 haematological cancers 362 367 6 01/17/22 20220115 NES 220115 To date, studies on anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine efficacy in blood cancers show that different responses may be observed according to the haematological malignancy diagnosis, stage of disease and ongoing treatment. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. [Extracted from the article]